164 related articles for article (PubMed ID: 31217479)
1. A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas.
Lin CC; Arkenau HT; Lu S; Sachdev J; de Castro Carpeño J; Mita M; Dziadziuszko R; Su WC; Bobilev D; Hughes L; Chan J; Zhang ZY; Weiss GJ
Br J Cancer; 2019 Jul; 121(2):131-138. PubMed ID: 31217479
[TBL] [Abstract][Full Text] [Related]
2. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
3. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.
Fukano R; Mori T; Sekimizu M; Choi I; Kada A; Saito AM; Asada R; Takeuchi K; Terauchi T; Tateishi U; Horibe K; Nagai H
Cancer Sci; 2020 Dec; 111(12):4540-4547. PubMed ID: 33010107
[TBL] [Abstract][Full Text] [Related]
4. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
[TBL] [Abstract][Full Text] [Related]
5. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study.
Fischer M; Moreno L; Ziegler DS; Marshall LV; Zwaan CM; Irwin MS; Casanova M; Sabado C; Wulff B; Stegert M; Wang L; Hurtado FK; Branle F; Geoerger B; Schulte JH
Lancet Oncol; 2021 Dec; 22(12):1764-1776. PubMed ID: 34780709
[TBL] [Abstract][Full Text] [Related]
6. Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study.
Ono A; Murakami H; Seto T; Shimizu T; Watanabe S; Takeshita S; Takeda K; Toyoshima J; Nagase I; Bahceci E; Morishita M; Morita S; Fukuoka M; Nakagawa K
Drugs R D; 2021 Mar; 21(1):65-78. PubMed ID: 33331996
[TBL] [Abstract][Full Text] [Related]
7. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
8. Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.
Horn L; Infante JR; Reckamp KL; Blumenschein GR; Leal TA; Waqar SN; Gitlitz BJ; Sanborn RE; Whisenant JG; Du L; Neal JW; Gockerman JP; Dukart G; Harrow K; Liang C; Gibbons JJ; Holzhausen A; Lovly CM; Wakelee HA
Clin Cancer Res; 2018 Jun; 24(12):2771-2779. PubMed ID: 29563138
[No Abstract] [Full Text] [Related]
9. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG
Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
[TBL] [Abstract][Full Text] [Related]
10. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Kim DW; Mehra R; Tan DSW; Felip E; Chow LQM; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Sutradhar S; Li S; Szczudlo T; Yovine A; Shaw AT
Lancet Oncol; 2016 Apr; 17(4):452-463. PubMed ID: 26973324
[TBL] [Abstract][Full Text] [Related]
11. Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study.
Xing P; Zhao Q; Zhang L; Wang H; Huang D; Hu P; Sun Y; Shi Y
BMC Med; 2022 Nov; 20(1):453. PubMed ID: 36424628
[TBL] [Abstract][Full Text] [Related]
12. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
[TBL] [Abstract][Full Text] [Related]
13. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
[TBL] [Abstract][Full Text] [Related]
14. Ceritinib in ALK-rearranged non-small-cell lung cancer.
Shaw AT; Kim DW; Mehra R; Tan DS; Felip E; Chow LQ; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Lau YY; Goldwasser M; Boral AL; Engelman JA
N Engl J Med; 2014 Mar; 370(13):1189-97. PubMed ID: 24670165
[TBL] [Abstract][Full Text] [Related]
15. Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial.
Shi Y; Fang J; Hao X; Zhang S; Liu Y; Wang L; Chen J; Hu Y; Hang X; Li J; Liu C; Zhang Y; Wang Z; Hu Y; Gu K; Huang J; Zhang L; Shan J; Ouyang W; Zhao Y; Zhuang W; Yu Y; Zhao J; Zhang H; Lu P; Li W; Si M; Ge M; Geng H
Signal Transduct Target Ther; 2022 Jan; 7(1):25. PubMed ID: 35087031
[TBL] [Abstract][Full Text] [Related]
16. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
17. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers.
Lewis NL; Lewis LD; Eder JP; Reddy NJ; Guo F; Pierce KJ; Olszanski AJ; Cohen RB
J Clin Oncol; 2009 Nov; 27(31):5262-9. PubMed ID: 19738123
[TBL] [Abstract][Full Text] [Related]
19. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
Seto T; Kiura K; Nishio M; Nakagawa K; Maemondo M; Inoue A; Hida T; Yamamoto N; Yoshioka H; Harada M; Ohe Y; Nogami N; Takeuchi K; Shimada T; Tanaka T; Tamura T
Lancet Oncol; 2013 Jun; 14(7):590-8. PubMed ID: 23639470
[TBL] [Abstract][Full Text] [Related]
20. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
